Weight loss medication is abused in Brazil more than in any other nation...

Good news for the French pharmaceutical company Sanofi Aventis is that the weight loss medication Acomplia has received full approval from the medical authorities in Brazil to be sold in the country. The sales of Acomplia are likely to be good in Brazil which has a growing obesity problem and which places a big emphasis on looking good on the beach.

Acomplia has been also approved for almost a year now in the European Union but has yet to receive the full approval for selling in the United States of America. Without a doubt the United States represents the largest weight loss medication market and the one that Sanofi Aventis are really banking their hopes on. Sanofi Aventis estimate that if they receive approval in all of the markets that they are aiming for they should be able to reach over $3 billion in sales yearly for their weight loss drug.

Acomplia is a unique weight loss medication in that it works on the receptors in the brain that control appetite and the drug makes you think that you are not hungry and therefore you eat less. In clinical testing it has shown be an extremely effective appetite suppressant and can really help overweight and obese people shed pounds.

At Ukmedix News we know that Brazil has a serious obesity problem but it also has a serious problem with the abuse of weight loss medication and while Acomplia is likely to help thousands of genuine obesity sufferers it is also probable that it will be abused by people who really should not be using it. The rules regarding the sale of weight loss medication are very lax in Brazil.

Weight loss medication is abused in Brazil more than in any other nation in the world according to a United Nations report and it is likely that fake copies of the Acomplia weight loss drug will soon appear on the market over there and unsuspecting customers will be tricked into buying it.